1/ 📢 Just published in NEJM AI: We take a critical look at Canada’s attempt to regulate artificial intelligence through the Artificial Intelligence and Data Act (AIDA). Our focus: where it fell short—especially in health care—and how to move forward. 🔗

A new commentary examines the shortcomings of Canada’s proposed Artificial Intelligence and Data Act and argues for a more targeted, sector-specific approach to ensure patient safety, transparency, and responsible innovation in future AI legislation. https://t.co/UyJakYUWZI

Extremely proud to announce: Journal Impact Factor for NeuroOncology Advances is now at 4.1 As Editor-in-Chief I am grateful to colleagues as associate editors & editorial board Most importantly thank you to the #authors #readers #patients #reviewers #researchers @EditorNeuro

Check out our article in @NEJM_AI. Canada is currently at a cross roads in AI regulation #cdnpoli

Published now in @NEJM_AI As #AI shapes what we do in health care we need to remain at the forefront the framework to regulate implementation Congratulations to @ahishaque in putting together a thought provoking piece @UofTNeuroSurge @UofTSurgery @MayoClinic @MayoClinicNeuro

6/ Huge thanks to my co-author @AbdiAidid, supervisor @gelarehzadeh, and to @NEJM_AI for publishing this work. Canada now has the chance to lead in responsible, health-specific AI regulation 🔗 https://t.co/bPge3MZEGE #AI #healthTech #MedAI #digitalhealth #cdnpoli #Canada

5/ Canada’s experience holds global lessons. AIDA’s structure reflected competing pressures—from EU-style rigor to U.S.-style flexibility—but ultimately left health care underprotected. Precision in law is essential for safe AI.

4/ We propose 3 reforms for future legislation: ✔ A centralized AI oversight body with sectoral divisions ✔ A tiered risk framework for clinical AI tools ✔ Decoupling AI regulation from privacy law, while coordinating both

3/ We argue that generic, cross-sector regulation isn’t enough for health care. Clinical AI tools require tailored oversight that addresses bias, safety, transparency, and accountability.

2/ AIDA was Canada’s first legislative attempt to regulate AI. It aimed for a risk-based framework—but lacked clarity, sector-specific oversight, and enforceable standards, especially for high-risk clinical applications.

Great turn out from @UofTNeuroSurge #AANS2025 @AANSNeuro

Amid the excitement around AI, Chef Asma Khan brought a powerful reminder at #AANS2025: “The great thing right now is AI, but the greatest thing is humanity.” Innovation moves us forward, but it’s humanity that gives it meaning. #AANS #AI #MedTwitter @Asma_KhanLDN

Special thanks to @gelarehzadeh for her gracious support and mentorship through the project!

Are LLMs ready to integrate in brain tumour care? We tested GPT-4o on MRIs of meningiomas and glioblastomas. It gets lots right, but also misses on some critical points. https://t.co/T4UwGCu34x #AI #Neurosurgery #radiology #medtwitter #ChatGPT

Very informative talk by Dr. Rutka today on the recent advancements in brainstem gliomas hosted by AANS/CNS. Particular emphasis on FUS led by efforts of Dr. Lipsman @JamesRutka @hadjiMDPhD @AANSNeuro @NSTumorSection @DrNirLipsman @Sunnybrook @SickKidsNews @UofTNeuroSurge

Dr. Zadeh delivered an outstanding lecture as their Dorothy Klenke Nash Lecturer at UPMC, presenting her work on advancing the understanding of meningiomas. A real tour de force in neuro-oncology and skull base @gelarehzadeh @MayoClinicNeuro @UPMC @hadjiMDPhD @DrRFriedlander

Warm welcome to the newest incoming residents to the program! @UofTNeuroSurge

my version of #Oscars

Congrats @FarshadNassiri ! Very well deserved

Congratulations to Dr Husain Shakil @UofTSurgery @UofTNeuroSurge resident for award winning presentations today @spinesection in Tampa and for earning cover figure for @TheJNS JNS:Spine February issue!